Fortress Biotech Croissance future
Future contrôle des critères 2/6
Les bénéfices de Fortress Biotech devraient diminuer de 73.3% par an tandis que son chiffre d'affaires annuel devrait croître de 42.1% par an. Le BPA devrait croître de en baisse de 87.5% par an.
Informations clés
-73.3%
Taux de croissance des bénéfices
-87.49%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 42.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 18 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 12
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.Mise à jour du récit • Apr 25
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.Mise à jour du récit • Apr 11
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.Mise à jour du récit • Mar 27
FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Mise à jour du récit • Mar 12
FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).Mise à jour du récit • Feb 26
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Seeking Alpha • Feb 20
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Summary Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO’s subsidiaries give it optionality across multiple subsidiaries, equity stakes, and royalty streams. FBIO’s Journey Medical assets give it its branded dermatology portfolio. The newly approved Emrosi provides near-term revenues. But more importantly, Zycubo (CUTX-101) for Menkes disease was FDA-approved in January 2026. This created a Rare Pediatric Disease PRV for FBIO. PRVs can be extremely valuable, and given FBIO’s microcap status, it could be a major upside catalyst if they sell it at a good price. Read the full article on Seeking AlphaMise à jour du récit • Feb 11
FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Article d’analyse • Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...Mise à jour du récit • Jan 28
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.Mise à jour du récit • Jan 12
FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).Mise à jour du récit • Dec 26
FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earningsArticle d’analyse • Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Mise à jour du récit • Dec 12
FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.Article d’analyse • Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
Mise à jour du récit • Aug 19
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.Article d’analyse • Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...Nouveau récit • Jul 06
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Article d’analyse • Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Article d’analyse • Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...Article d’analyse • Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...Article d’analyse • Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...Article d’analyse • Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 134 | 21 | N/A | N/A | 2 |
| 12/31/2026 | 80 | 91 | N/A | N/A | 1 |
| 3/31/2026 | 66 | 119 | 158 | 158 | N/A |
| 12/31/2025 | 63 | -2 | -66 | -66 | N/A |
| 9/30/2025 | 62 | -5 | -81 | -66 | N/A |
| 6/30/2025 | 59 | -24 | -95 | -80 | N/A |
| 3/31/2025 | 58 | -51 | -89 | -74 | N/A |
| 12/31/2024 | 58 | -56 | -95 | -80 | N/A |
| 9/30/2024 | 82 | -58 | -102 | -102 | N/A |
| 6/30/2024 | 83 | -49 | -100 | -99 | N/A |
| 3/31/2024 | 85 | -63 | -113 | -110 | N/A |
| 12/31/2023 | 85 | -69 | -136 | -128 | N/A |
| 9/30/2023 | 62 | -86 | -150 | -141 | N/A |
| 6/30/2023 | 63 | -104 | -176 | -168 | N/A |
| 3/31/2023 | 64 | -100 | -182 | -176 | N/A |
| 12/31/2022 | 76 | -95 | -202 | -179 | N/A |
| 9/30/2022 | 78 | -97 | -196 | -170 | N/A |
| 6/30/2022 | 82 | -93 | -181 | -149 | N/A |
| 3/31/2022 | 81 | -74 | -179 | -142 | N/A |
| 12/31/2021 | 69 | -65 | -133 | -117 | N/A |
| 9/30/2021 | 64 | -38 | -113 | -98 | N/A |
| 6/30/2021 | 53 | -33 | -110 | -101 | N/A |
| 3/31/2021 | 44 | -43 | -89 | -83 | N/A |
| 12/31/2020 | 46 | -47 | -91 | -84 | N/A |
| 9/30/2020 | 43 | -57 | -99 | -88 | N/A |
| 6/30/2020 | 43 | -54 | -92 | -81 | N/A |
| 3/31/2020 | 43 | -54 | -102 | -92 | N/A |
| 12/31/2019 | 37 | -40 | N/A | -95 | N/A |
| 9/30/2019 | 34 | -45 | N/A | -92 | N/A |
| 6/30/2019 | 30 | -51 | N/A | -101 | N/A |
| 3/31/2019 | 27 | -53 | N/A | -96 | N/A |
| 12/31/2018 | 27 | -73 | N/A | -99 | N/A |
| 9/30/2018 | -107 | -61 | N/A | -98 | N/A |
| 6/30/2018 | -65 | -69 | N/A | -98 | N/A |
| 3/31/2018 | -22 | -72 | N/A | -98 | N/A |
| 12/31/2017 | 17 | -65 | N/A | -81 | N/A |
| 9/30/2017 | 155 | -74 | N/A | -78 | N/A |
| 6/30/2017 | 109 | -60 | N/A | -62 | N/A |
| 3/31/2017 | 61 | -55 | N/A | -46 | N/A |
| 12/31/2016 | 16 | -55 | N/A | -46 | N/A |
| 9/30/2016 | 4 | -50 | N/A | -35 | N/A |
| 6/30/2016 | 3 | -55 | N/A | -31 | N/A |
| 3/31/2016 | 1 | -49 | N/A | -30 | N/A |
| 12/31/2015 | 1 | -48 | N/A | -20 | N/A |
| 9/30/2015 | 1 | -40 | N/A | -17 | N/A |
| 6/30/2015 | 1 | -27 | N/A | -14 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Les bénéfices de FBIO devraient diminuer au cours des 3 prochaines années ( -73.3% par an).
Bénéfices vs marché: Les bénéfices de FBIO devraient diminuer au cours des 3 prochaines années ( -73.3% par an).
Croissance élevée des bénéfices: Les bénéfices de FBIO devraient baisser au cours des trois prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de FBIO ( 42.1% par an) devrait croître plus rapidement que le marché US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de FBIO ( 42.1% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de FBIO devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 19:50 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Fortress Biotech, Inc. est couverte par 13 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |